NCT07414394进行中（未招募）3 期
A Randomized, Double-Blind, Double-Dummy, Multi-Center, Phase III Study Comparing the Efficacy and Safety of Tigulixostat (IBI128) and Febuxostat in Chinese Subjects With Gout
Innovent Biologics Technology Limited (Shanghai R&D Center)2 个研究点 分布在 1 个国家目标入组 600 人开始时间: 2026年3月17日最近更新:
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 600
- 试验地点
- 2
- 主要终点
- Proportion of Participants Achieving Serum Uric Acid <360 μmol/L at Week 24
研究概览
简要总结
The primary purpose of this study is to compare the efficacy of Tigulixostat (IBI128) versus Febuxostat on the proportion of Chinese adults with gout achieving a serum uric acid (sUA) level < 360 μmol/L at Week 24. The study also evaluates safety, gout attacks, kidney function, inflammation, and quality of life over 52 weeks of treatment. Approximately 600 eligible participants will be randomized to receive either Tigulixostat or Febuxostat.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must meet all of the following criteria to be eligible for the study:
- •Age ≥ 18 years, male or female.
- •Body mass index (BMI) between 18 and 40 kg/m².
- •Diagnosed with gout according to the 2015 ACR/EULAR classification criteria.
- •Serum uric acid (sUA) at screening:
- •≥ 480 μmol/L for subjects without comorbidities;
- •≥ 420 μmol/L for subjects with at least one concurrent condition (e.g., ≥ 2 gout attacks/year, tophi, chronic gouty arthritis, hypertension, diabetes, dyslipidemia, age of onset < 40 years).
- •Voluntarily sign the informed consent form and agree to strictly follow the protocol requirements.
排除标准
- •Participants who meet any of the following criteria will be excluded from the study:
- •History of allergy or intolerance to any component of febuxostat or Tigulixostat, or previous evidence of poor response to febuxostat treatment (e.g., sUA > 420 μmol/L after ≥ 6 weeks of febuxostat ≥ 40 mg).
- •Acute gout attack within 4 weeks prior to screening or from screening to first dose.
- •Use of uric acid-lowering drugs (e.g., allopurinol, febuxostat, probenecid, benzbromarone, dotinurad, recombinant uricase; excluding sodium bicarbonate) within 2 weeks before screening.
- •Hyperuricemia caused by secondary gout (e.g., myeloproliferative disease, tumor, organ transplantation, enzyme deficiency, renal tubular dysfunction, lead poisoning, psoriasis, medications), excluding hyperuricemia due to renal insufficiency.
- •Use of the following medications or therapies prior to screening or planned during the study:
- •(1)Prior urate oxidase treatment; (2)Concomitant medications affecting uric acid levels within 4 weeks before screening with dose adjustments (e.g., losartan, calcium channel blockers, diuretics, fenofibrate, atorvastatin, α-glucosidase inhibitors, insulin sensitizers, DPP4 inhibitors, SGLT2 inhibitors, metformin, GLP-1 receptor agonists, pyrazinamide, aspirin); (3)Long-term drugs dependent on xanthine oxidase metabolism (e.g., azathioprine, mercaptopurine); (4)Oral corticosteroids ≥ 10 consecutive days, or intramuscular/intravenous/intra-articular corticosteroid injection within 4 weeks before screening; (5)Biologics (e.g., TNF-α inhibitors, IL-1 inhibitors, IL-6 inhibitors) within 12 weeks before screening.
- •6. History or evidence of any of the following diseases:
- •Xanthinuria, Lech-Nyhan syndrome, 5-phosphoribosyl-1-pyrophosphate synthetase superactivity, congenital myogenic hyperuricemia, rhabdomyolysis;
- •Uncontrolled severe pain not caused by gout;
- •Cardiovascular events or conditions within 6 months (e.g., acute MI, ACS, unstable angina, CABG, PCI, TIA, cerebrovascular accident, severe arrhythmia, NYHA class III/IV heart failure);
- •QTcF ≥ 480 ms or history of prolonged QTc interval;
- •Poorly controlled hypertension (SBP ≥ 160 mmHg or DBP ≥ 100 mmHg) or recent adjustment of antihypertensive drugs;
- •Poorly controlled diabetes (HbA1c ≥ 9.0%);
- •Autoimmune or inflammatory diseases requiring systemic immunosuppressive treatment;
- •Active peptic ulcer or GI bleeding within 1 month;
- •Diseases affecting drug absorption (e.g., IBS, IBD);
- •Active hepatitis B, C, HIV, or syphilis infection;
- •Active or untreated malignancy within 5 years, except specified low-risk cancers;
- •Thyroid dysfunction requiring treatment.
- •Laboratory abnormalities:
- •(1)total bilirubin > 2×ULN, ALT or AST > 3×ULN; (2)eGFR < 30 mL/min/1.73 m².
- •Pregnant or lactating women, or participants unwilling to use effective contraception during the study and for 8 weeks after study end.
- •9. History of alcohol or drug abuse (weekly alcohol > 21 units for males, > 14 units for females).
- •10. Blood donation or loss ≥ 400 mL within 3 months, or prior blood transfusion.
- •11. Participation in another interventional clinical trial within 3 months or 5 half-lives of prior investigational drug.
- •12. Major surgery within 3 months, incomplete recovery, or planned major surgery during study.
- •13. Presence of mental illness deemed inappropriate for study participation by the investigator.
- •14. Any other condition judged by the investigator to potentially affect study efficacy or safety evaluation.
研究组 & 干预措施
Tigulixostat
Experimental
干预措施: Tigulixostat (Drug)
Febuxostat
Active Comparator
干预措施: Febuxostat (Drug)
结局指标
主要结局
Proportion of Participants Achieving Serum Uric Acid <360 μmol/L at Week 24
时间窗: At Week 24
Percentage of participants with serum uric acid (sUA) level below 360 μmol/L at Week 24 after randomized treatment with Tigulixostat (IBI128) or Febuxostat in Chinese participants with gout.
次要结局
- Proportion of Participants Achieving Serum Uric Acid <360 μmol/L at Week 12(At Week 12)
- Proportion of Participants with Serum Uric Acid <360 μmol/L at Each Scheduled Visit(At Week 0, 2, 4, 8, 12, 16, 20, 24, 32, 42, and 52)
- Proportion of Participants Achieving Serum Uric Acid <300 μmol/L at Each Scheduled Visit(At Week 0, 2, 4, 8, 12, 16, 20, 24, 32, 42, and 52)
- Proportion of Participants Achieving Serum Uric Acid <240 μmol/L at Each Scheduled Visit(At Week 0, 2, 4, 8, 12, 16, 20, 24, 32, 42, and 52)
- Mean Change From Baseline in Serum Uric Acid Level at Each Scheduled Visit(At Week 0, 2, 4, 8, 12, 16, 20, 24, 32, 42, and 52)
- Mean Percent Change From Baseline in Serum Uric Acid Level at Each Scheduled Visit(At Week 0, 2, 4, 8, 12, 16, 20, 24, 32, 42, and 52)
- Number of Participants with Adverse Events (AEs)/Serious Adverse Events (SAEs)(Baseline through Week 54 (end of safety follow-up))
- Proportion and Number of Gout Flares per Participant(Every 4 weeks from first dose through Week 52)
- Change From Baseline in Renal Function Parameters(At Week 12, 24, and 52)
- Change From Baseline in Renal Function Parameters(At Weeks 12, 24, and 52)
- Change From Baseline in Inflammatory and Deposition-Related Parameters(At Weeks 12, 24, and 52)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
3 期
A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adults with chronic kidney disease (CKD) and high blood pressure2023-506460-14-00Astrazeneca AB1,310
招募中
2 期
Safety and efficacy of IMCgp100 versus Investigator’s Choice in advanced uveal melanoma2024-517290-24-00Immunocore Limited96
招募中
3 期
A trial to learn if Dato-DXd with rilvegostomig, or rilvegostomig alone, is safe and works compared with pembrolizumab in people who have advanced non-squamous non-small cell lung cancer (NSCLC) with high levels of the PD-L1 protein2023-505077-32-00AstraZeneca AB199
招募中
3 期
A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (GLORA Study)2023-508005-24-00Ascentage Pharma Group Inc.232
招募中
4 期
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral AgentsType 2 DiabetesNCT07307235Shanghai Zhongshan Hospital1,316